Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.75 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | GMNN | O75496 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956590 | 0.91 | PDE5A (1.00) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 | |
| SCHEMBL5564827 | 0.88 | PDE5A (0.77) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 | |
| SCHEMBL5564678 | 0.88 | PDE5A (0.77) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 | |
| SCHEMBL5560137 | 0.87 | PDE5A (0.84) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 | |
| SCHEMBL3237858 | 0.87 | PDE5A (0.75) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 | |
| SCHEMBL5107975 | 0.86 | PDE5A (0.85) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 | |
| SCHEMBL187837 | 0.86 | PDE5A (1.00) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 | |
| SCHEMBL29352550 | 0.86 | PDE5A (1.00) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 | |
| SCHEMBL5559790 | 0.86 | PDE5A (0.77) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 | |
| SCHEMBL5563000 | 0.84 | PDE5A (0.71) | PDE5AHIF1AEPAS1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO INC. (US) | 2006-04-19 | — | — | EP | claimed |
| US-20050187276-A1 | Compounds, compositions and methods | BIZBIOTECH CO., LTD. (KR) | 2005-08-25 | — | — | US | claimed |
| WO-2005030121-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO, INC. (US) | 2005-04-07 | — | — | WO | claimed |
| US-7226941-B2 | Compound for treating angiogenesis | HIF BIO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1646382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO INC. (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050187276-A1 | Compounds, compositions and methods | BIZBIOTECH CO., LTD. (KR) | 2005-08-25 | — | — | US | disclosed |
| WO-2005030121-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187276-A1 | Compounds, compositions and methods | HIF1A, HIF1AN, EGLN3 | PDE5A 1987/4885HIF1A 1/4885EPAS1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.